Integrated peptide and oligonucleotide biosynthesis with site‑defined conjugation
Peptide–siRNA / ASO / aptamer
Flexible Chemistries
Bench to Kilo Scale
ISO 9001:2015/ISO 13485:2016
45+ Years of Expertise
U.S. Facilities – Texas
Peptide–oligonucleotide conjugation at Bio‑Synthesis uniquely integrates
in‑house peptide synthesis and oligonucleotide manufacturing into a single, tightly
controlled workflow.
Unlike providers that focus only on oligonucleotides or outsource peptide components, we design, synthesize,
conjugate, purify, and analyze both molecules internally.
This unified biosynthesis approach reduces hand‑off risk, shortens timelines, and ensures that linker
chemistry,
attachment site, purification strategy, and QC are aligned from the start.
It is particularly important for peptide–DNA, peptide–RNA,
peptide–ASO, and peptide–siRNA conjugates, where small deviations in
purity,
stoichiometry, or handle placement can significantly affect biological performance.
By combining expert peptide chemistry, automated oligonucleotide
synthesis,
and site‑specific bioconjugation, we deliver reproducible peptide–oligonucleotide
conjugates
supported by fit‑for‑purpose analytical confirmation.
Peptide–oligonucleotide conjugation is the covalent attachment of a peptide to an
oligonucleotide (DNA or RNA) to add functionality that nucleic acids alone often lack.
Common goals include enhanced cellular uptake (CPPs), targeted delivery
(receptor-binding peptides), endosomal escape, improved serum stability, or controlled
presentation on surfaces.
Because peptides and oligonucleotides behave very differently (charge, solubility, stability), successful
POC synthesis depends on a practical plan:
choose a site of attachment, select a linker chemistry compatible with
both components, and define a QC strategy that confirms identity, purity, and conjugation
ratio.